title: The cytokine mRNA increase induced by withdrawal from chronic ethanol in the sterile environment of brain is mediated by CRF and HMGB1 release.
abstract: BACKGROUND
  Many neurobiological factors may initiate and sustain alcoholism. Recently, dysregulation of the neuroimmune system by chronic ethanol (CE) has implicated Toll-like receptor 4 (TLR4) activation. Even though TLR4s are linked to CE initiation of brain cytokine mRNAs, the means by which CE influences neuroimmune signaling in brain in the absence of infection remains uncertain. Therefore, the hypothesis is tested that release of an endogenous TLR4 agonist, high-mobility group box 1 (HMGB1) and/or corticotropin-releasing factor (CRF) during CE withdrawal are responsible for CE protocols increasing cytokine mRNAs.
  
  
  METHODS
  Acute ethanol (EtOH; 2.75 g/kg) and acute lipopolysaccharide (LPS; 250 μg/kg) dosing on cytokine mRNAs are first compared. Then, the effects of chronic LPS exposure (250 μg/kg for 10 days) on cytokine mRNAs are compared with changes induced by CE protocols (15 days of continuous 7% EtOH diet [CE protocol] or 3 intermittent 5-day cycles of 7% EtOH diet [CIE protocol]). Additionally, TLR4, HMGB1, and downstream effector mRNAs are assessed after CE, CIE, and chronic LPS. To test whether HMGB1 and/or CRF support the CE withdrawal increase in cytokine mRNAs, the HMGB1 antagonists, glycyrrhizin and ethyl pyruvate, and a CRF1 receptor antagonist (CRF1RA) are administered during 24 hours of CE withdrawal.
  
  
  RESULTS
  While cytokine mRNAs were not increased following acute EtOH, acute LPS increased all cytokine mRNAs 4 hours after injection. CE produced no change in cytokine mRNAs prior to CE removal; however, the CE and CIE protocols increased cytokine mRNAs by 24 hours after withdrawal. In contrast, chronic LPS produced no cytokine mRNA changes 24 hours after LPS dosing. TLR4 mRNA was elevated 24 hours following both CE protocols and chronic LPS exposure. While chronic LPS had no effect on HMGB1 mRNA, withdrawal from CE protocols significantly elevated HMGB1 mRNA. Systemic administration of HMGB1 antagonists or a CRF1RA significantly reduced the cytokine mRNA increase following CE withdrawal. The CRF1RA and the HMGB1 antagonist, ethyl pyruvate, also reduced the HMGB1 mRNA increase that followed CE withdrawal.
  
  
  CONCLUSIONS
  By blocking HMGB1 or CRF action during CE withdrawal, evidence is provided that HMGB1 and CRF release are critical for the CE withdrawal induction of selected brain cytokine mRNAs. Consequently, these results clarify a means by which withdrawal from CE exposure activates neuroimmune function in the sterile milieu of brain.
authors.affiliation: Bowles Center for Alcohol Studies, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Curriculum in Neurobiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
authors.forename: Buddy A
authors.initials: BA
authors.lastname: Whitman
authors.forename: Darin J
authors.initials: DJ
authors.lastname: Knapp
authors.forename: David F
authors.initials: DF
authors.lastname: Werner
authors.forename: Fulton T
authors.initials: FT
authors.lastname: Crews
authors.forename: George R
authors.initials: GR
authors.lastname: Breese
mesh_terms: D000818:Animals; D001921:Brain / Q000503:physiopathology*; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000502:physiology*; D016207:Cytokines / Q000235:genetics*; D000431:Ethanol / Q000008:administration & dosage*; D024243:HMGB1 Protein / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology*; D051197:Toll-Like Receptor 4 / Q000235:genetics
chemical_list: D016207:Cytokines; D024243:HMGB1 Protein; D008070:Lipopolysaccharides; D012333:RNA, Messenger; C495347:Tlr4 protein, rat; D051197:Toll-Like Receptor 4; D000431:Ethanol; D003346:Corticotropin-Releasing Hormone
keywords: CRF1 Receptor Antagonist; Chronic Ethanol Withdrawal; Cytokines; HMGB1 Antagonists; Lipopolysaccharide
references.citation: Brain Behav Immun. 2011 Jun;25 Suppl 1:S4-S12
references.pmid: 21402143
references.citation: Nat Med. 2010 Apr;16(4):413-9
references.pmid: 20348922
references.citation: Chem Biol. 2007 Apr;14(4):345-7
references.pmid: 17462568
references.citation: Br J Pharmacol. 2012 Mar;165(5):1319-29
references.pmid: 21955045
references.citation: Neuropharmacology. 2011 Oct-Nov;61(5-6):975-80
references.pmid: 21752338
references.citation: Alcohol Clin Exp Res. 2008 Aug;32(8):1350-60
references.pmid: 18540921
references.citation: J Immunol. 2009 Oct 1;183(7):4733-44
references.pmid: 19752239
references.citation: J Immunol. 2005 Nov 15;175(10):6893-9
references.pmid: 16272348
references.citation: Annu Rev Immunol. 1994;12:141-79
references.pmid: 8011280
references.citation: Biol Psychiatry. 2013 Apr 1;73(7):602-12
references.pmid: 23206318
references.citation: J Neurochem. 2007 Oct;103(2):590-603
references.pmid: 17666052
references.citation: Exp Neurol. 2008 Apr;210(2):349-58
references.pmid: 18190912
references.citation: Psychopharmacology (Berl). 2011 Nov;218(1):203-15
references.pmid: 21735074
references.citation: Alcohol Clin Exp Res. 1990 Jun;14(3):394-9
references.pmid: 2378423
references.citation: Annu Rev Immunol. 2011;29:139-62
references.pmid: 21219181
references.citation: J Inflamm. 1995;45(1):13-26
references.pmid: 7583350
references.citation: Psychopharmacology (Berl). 2005 Apr;178(4):367-80
references.pmid: 15765253
references.citation: J Neurosci. 2010 Jun 16;30(24):8285-95
references.pmid: 20554880
references.citation: Brain Behav Immun. 2011 Jun;25 Suppl 1:S80-91
references.pmid: 21352907
references.citation: Trends Biochem Sci. 2002 Sep;27(9):474-82
references.pmid: 12217523
references.citation: J Neuroinflammation. 2008 Mar 18;5:10
references.pmid: 18348728
references.citation: J Pharmacol Exp Ther. 1983 Dec;227(3):663-70
references.pmid: 6317842
references.citation: Glia. 2007 Apr 1;55(5):453-62
references.pmid: 17203472
references.citation: Transl Stroke Res. 2010 Dec 1;1(4):252-260
references.pmid: 21339866
references.citation: Mol Immunol. 2008 Apr;45(7):2007-16
references.pmid: 18061674
references.citation: Hepatology. 2001 Jul;34(1):101-8
references.pmid: 11431739
references.citation: J Exp Med. 2003 Oct 6;198(7):1043-55
references.pmid: 14517278
references.citation: Neuropsychopharmacology. 2008 Mar;33(4):867-76
references.pmid: 17551540
references.citation: J Leukoc Biol. 2005 Jul;78(1):1-8
references.pmid: 15734795
references.citation: Mediators Inflamm. 2011;2011:807142
references.pmid: 21772666
references.citation: Alcohol Clin Exp Res. 2002 Aug;26(8):1259-68
references.pmid: 12198403
references.citation: Alcohol Clin Exp Res. 2003 Dec;27(12):1979-86
references.pmid: 14691386
references.citation: Eur J Neurosci. 2007 Jan;25(2):541-50
references.pmid: 17284196
references.citation: Brain Behav Immun. 2011 Jun;25 Suppl 1:S146-54
references.pmid: 21377524
references.citation: Pharmacol Ther. 2011 Feb;129(2):149-71
references.pmid: 20951730
references.citation: Arterioscler Thromb Vasc Biol. 2011 May;31(5):1024-32
references.pmid: 21372296
references.citation: Alcohol. 2004 Feb;32(2):101-11
references.pmid: 15163561
references.citation: Brain Res Rev. 2009 Mar;59(2):278-92
references.pmid: 18822314
references.citation: Alcohol Clin Exp Res. 2010 May;34(5):777-89
references.pmid: 20201932
references.citation: EMBO J. 2001 Aug 15;20(16):4337-40
references.pmid: 11500360
references.citation: Nat Rev Immunol. 2004 Jul;4(7):499-511
references.pmid: 15229469
references.citation: J Leukoc Biol. 2009 Sep;86(3):633-43
references.pmid: 19454652
references.citation: Shock. 2006 Aug;26(2):174-9
references.pmid: 16878026
references.citation: J Cell Sci. 2002 Jun 15;115(Pt 12):2603-11
references.pmid: 12045230
references.citation: Crit Care Med. 2002 Jan;30(1 Supp):S64-S73
references.pmid: 11891406
references.citation: Chem Biol. 2007 Apr;14(4):431-41
references.pmid: 17462578
references.citation: Microbes Infect. 2002 Jul;4(8):837-51
references.pmid: 12270731
references.citation: Immunology. 2004 Oct;113(2):153-62
references.pmid: 15379975
references.citation: Neuroscience. 2011 Aug 11;188:48-54
references.pmid: 21605631